Patent problem: The Health Ministry is paying high prices for many crucial drugs while generic versions can be obtained at lower prices.
THE PHARMACEUTICAL company for an important HIV/AIDS drug that combines Lopinavir and Ritonavir did not file for patents on the two base compounds in Malaysia.
However, between 1999 and 2006, several secondary patents were filed on the compounds and granted by the Malaysian intellectual property office.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
